A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: Preliminary results of a multi-center phase II trial
Gregory Friberg,Amit M. Oza,Robert J. Morgan,Everett E. Vokes,David R. Gandara,Gini F. Fleming +5 more
TL;DR: The first stage of accrual is complete and further enrollment is on hold pending continued efficacy evaluation of BE in pts with recurrent OC, primary peritoneal, and FT cancer, and there appeared to be an increased rate of bowel perforation.
Journal ArticleDOI
Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer.
Paul E. Goss,Kathrin Strasser,Ricardo Marques,Mark Clemons,Amit M. Oza,Rakesh Goel,Martin E. Blackstein,Leonard Kaizer,Ernest E. Sterns,Jean-Marc Nabholtz,Roland De Coster,Michael Crump,Mohamed Abdolell,Shangle Qi +13 more
TL;DR: Three phase II studies were conducted to determine the efficacy and tolerability of liarozole fumarate, a retinoic acid metabolism blocking agent (RAMBA) and aromatase inhibitor and demonstrated dose-dependent anti-tumor effects in the rats, only partially overcome by coadministration of estradiol.
Journal ArticleDOI
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
Saeed Rafii,Charlie Gourley,Rajiv Kumar,Elena Geuna,Joo Ern Ang,Tzyvia Rye,Lee-may Chen,Ronnie Shapira-Frommer,Michael Friedlander,Ursula A. Matulonis,Jacques De Greve,Amit M. Oza,Susana Banerjee,L Rhoda Molife,Martin Gore,Stan B. Kaye,Timothy A. Yap +16 more
TL;DR: PTPI may be used to refine the prediction of response to PARP inhibition based on the conventional categorization of platinum sensitivity, an international multicenter retrospective study on the basis of baseline clinical characteristics of patients with advanced BRCA1/2 mutation ovarian cancers.
Journal ArticleDOI
Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
Sheray N. Chin,Victoria Pinto,Barry P. Rosen,Amit M. Oza,Jason Dodge,Joan Murphy,Helen Mackay +6 more
TL;DR: A prospective evaluation of an ambulatory intraperitoneal (IP) /intravenous (IV) chemotherapy regimen for women with epithelial ovarian carcinoma and found this regimen is convenient for patients and potentially more cost effective than other published IP cisplatin-based regimens.
Journal ArticleDOI
COVID-19 Testing in Patients with Cancer: Does One Size Fit All?
Ainhoa Madariaga,Michelle McMullen,Semira Sheikh,Rajat Kumar,Fei-Fei Liu,Camilla Zimmermann,Shahid Husain,Gelareh Zadeh,Amit M. Oza +8 more
TL;DR: A comprehensive review of the available evidence regarding SARS-CoV-2 testing in asymptomatic cancer patients is performed, and the approach adopted at Princess Margaret Cancer Centre (Toronto, Canada) is described as a core component of COVID-19 control.